ACE and diabetes mellitus: Al-Mallah reported a relative risk of 0.78 (95%CI 0.70-0.88) for the development of diabetes with ACE inhibitors and a relative risk of 0.8 (95%CI 0.75-0.86) for angiotensin receptor blockers versus non-RAS based treatments [24].